Replication stress entails the improper progression of DNA replication. In cancer cells, including breast cancer cells, an important cause of replication stress is oncogene activation. Importantly, tumors with high levels of replication stress may have different clinical behavior, and high levels of replication stress appear to be a vulnerability of cancer cells, which may be therapeutically targeted by novel molecularly targeted agents.
year. One third of these women subsequently die of this disease, accounting for ~14% of all cancer-related deaths in women 1 . Therefore, there is an urgent clinical need for improved breast cancer treatment.
Breast cancers are very heterogeneous, and multiple classification methods have been developed to stratify patient groups. Using gene expression profiling, at least six major breast cancer subtypes have been defined, including 'normal-like', 'luminal A', 'luminal B', 'HER2-enriched', 'claudin-low' and 'basal-like' 2 . Furthermore, combining copy number variations with gene expression analysis allowed identification of ten clusters that are associated with differential clinical outcome 3 .
Although multiple classification systems are used in a research context, in standard care breast cancers are subtyped based on the expression of the estrogen and progesterone receptors (ER, PR) and the human epidermal growth factor receptor 2 (HER2), as these receptors are 'oncogenic drivers' and relevant drug targets. Breast cancers that do not express the ER, PR or HER2 -triple-negative breast cancers (TNBCs) -show a large degree of overlap with the intrinsic 'basal-like' and 'claudin-low' subtypes, and lack common 'druggable' aberrations. TNBC patients do not benefit from anti-hormonal or anti-HER2-targeted treatments, and rely on conventional chemotherapeutic regimens. These tumors display aggressive behavior, and account for ~15-20% of all invasive breast cancers 4 . Although initially high response rate to conventional chemotherapeutics are seen in TNBC, tumors often recur and women have a poor prognosis overall 4 .
Recent genomic analyses of breast cancers have not only underscored the absence of 'druggable' oncogenic drivers in TNBC, but also showed that these cancers share a profound genomic instability 5 . This phenomenon is characterized by continuous gains and losses of chromosomal fragments. As a consequence, genomic instability underlies the rapid acquisition of genomic aberrations that drive therapy failure 6 . Finding novel treatment options for genomically instable cancers is not only relevant for TNBCs, but also for other hard-to-treat cancers with extensive genomic instability, including ovarian and pancreatic cancers.
Evidence is increasingly pointing to replication stress as the driver of genomic instability 7, 8 .
During S-phase of the cell cycle, all DNA must be replicated in a coordinated manner to divide two complete copies of the genome between the two daughter cells. To replicate the entire genome in an orchestrated fashion, replication is initiated at certain genomic loci called 'replication origins' 8 . Replication origins are not fired simultaneously, but in a temporally controlled way. This sequential firing of the replication origins prevents exhaustion of the nucleotide pool and warrants the availability of essential components of the replication machinery as well as replication checkpoint proteins.
DNA replication can be frustrated in various ways, which is referred to as replication stress.
Multiple factors that cause replication stress have been identified, including secondary DNA structures or DNA-RNA hybrids at sites of ongoing transcription 7 . However, the most important source of replication stress appears to be the uncoordinated firing of replication origins due to oncogene activation 7, 8, 9, 10 . As a consequence, oncogene activation depletes the nucleotide pool, leading to slowing or complete stalling of replication forks 11 .
A relevant oncogene related to replication stress is c-Myc, which functions as a transcription factor 12 . c-Myc overexpression promotes cell growth 13 , elevates levels of reactive oxygen species 12 and causes cellular senescence in experimental models 14 . Another oncogene that has been identified to cause replication stress is Cyclin E. Overexpression of Cyclin E increases the activity of its binding partner Cyclin-dependent Kinase-2 (CDK2) and accelerates S-phase entry. Simultaneously, Cyclin E overexpression results in aberrant activation of origin firing and a consequent nucleotide pool depletion causing replication fork stalling and genomic instability 11, 15 . Likewise, the Cdc25a phosphatase activates CDKs, including CDK2, and promotes premature cell cycle progression and checkpoint bypass 16, 17, 18 .
Cells are equipped with multiple mechanisms to survive replication stress. During replication fork stalling, single-stranded DNA (ssDNA) is exposed and rapidly activates the so-called 'replication checkpoint', in which the ATR kinase is the central player 19 .
Activation of the replication checkpoint facilitates the rapid coating of ssDNA at replication forks by filaments of replication-Protein A (RPA), which in this process are phosphorylated by ATR 20,21 . RPA filaments subsequently protect and stabilize the otherwise fragile replication forks from nuclease-mediated degradation. When these stalled replication forks are not resolved in time, they can collapse and cause DNA double-strand breaks (DSBs).
DSBs rapidly activate the ATM kinase, which leads to activation of multiple downstream targets, including components of the cell cycle machinery and DNA repair pathways 21 . An important ATM substrate at DSBs, including collapsed replication forks, is the histone variant H2AX, which after phosphorylation at serine 139 is referred to as γ-H2AX 22 .
To mitigate the negative impact of replication stress on cellular viability, cancer cells have evolved replication stress-resolving mechanisms. Genomically instable tumors increasingly rely on these mechanisms, including cell cycle checkpoint responses, for their survival 23 . Therefore, components of these replication stress-resolving mechanisms, including the checkpoint kinases Wee1, ATR and Chk1, present promising targets for tumors with high levels of replication stress. Many of the data on replication stress in cancers were derived from experimental model systems. In order to implement novel therapeutic agents that target tumors with high levels of replication stress optimally, it is essential that an inventory is made of tumor subtypes that display replication stress. To this end, and to find potential biomarkers for tumors with high levels of replication stress, we examined replication stress levels in relation to oncogene expression and clinicopathological data in a consecutive well-defined series of breast cancer samples.
Results

Patient characteristics
The study population comprised 384 breast cancer patients ( Fig. 1a ), whose baseline clinical, pathological and treatment characteristics are summarized in Table 1 . Breast cancer patients were divided into four subtypes according to their hormone receptor status and HER2 expression. Molecular subtype analysis showed that our cohort consisted of n=161 ER|PR + HER2 -, n=90 ER|PR + HER2 + , n=27 ER|PR -HER2 + and n=106 ER|PR -HER2 -(TNBC) patients ( 
Levels of replication stress in breast cancer subtypes
To determine levels of replication stress, we immunohistochemically examined the expression of pRPA and γ-H2AX in treatment-naive breast cancer tissues. Representative immunohistochemical pRPA and γ-H2AX stainings are shown in Fig. 1b . Among the breast cancer subtypes, the highest pRPA staining scores were found in TNBC tumors (Table 3a , Fig. 2a ). Moreover, TNBC tumors also showed higher pRPA levels than non-TNBC tumors ( Fig. 2b, P=3 .79*10 -9 ). In addition, the γ-H2AX scores from TNBC tumors were significantly higher than in ER|PR + HER2and ER|PR + HER2 + subgroups (Table 3a , P<0.05 for all tests), followed by ER|PR -HER2 + tumors ( Fig. 2a ). Also, TNBC tumors displayed higher levels of γ-H2AX expression when compared to non-TNBCs ( Fig. 2b, P=3 .42*10 -4 ).
These data show that the expression of replication stress markers varies among breast cancer subtypes, with TNBCs and ER|PR -HER2 + tumors exhibiting the highest levels.
Expression of Cdc25a, Cyclin E and c-Myc in breast cancer subtypes
We next examined the expression levels of Cyclin E (encoded by CCNE1) and c-Myc (encoded by MYC), two oncogenes that are frequently amplified in TNBC, and have been associated with replication stress in experimental models 29, 30, 31, 32 . For Cyclin E, we separately assessed nuclear and cytoplasmic Cyclin E ( Fig. 1c ), since cytoplasmic Cyclin E has been related to reduced breast cancer survival 27, 33 . We also assessed expression of the Cdc25a phosphatase ( Fig. 1c ). Although Cdc25a is less frequently overexpressed in breast cancer 16 , Cdc25a overexpression is frequently used to induce replication stress in experimental models 34 , and has been linked to oncogenic activity 35, 36 , and for that reason was included in our analysis.
Expression levels of nuclear Cyclin E were significantly higher in TNBC than in the other breast cancer subtypes ( Fig. 2a , Table 3b , P<0.05 for all tests). In contrast, cytoplasmic Cyclin E levels were high in both TNBC and ER|PR -HER2 + tumors, compared to ER|PR + HER2tumors ( Fig. 2a , Table 3b , P<0.05 for all tests). Expression levels of c-Myc were also higher in TNBC ( Fig. 2a , Table 3b , P<0.001) compared to the other subgroups.
Even though TNBC tumors also displayed the highest levels of Cdc25a (Table 3b ), these differences were not statistically significant ( Fig. 2a and Table 3b ). These findings show that TNBCs displayed the highest levels of nuclear Cyclin E and c-Myc. In contrast, Cdc25a expression was similarly distributed among breast cancer subtypes.
Since the highest expression levels of c-Myc and Cyclin E as well as replication stress markers were observed in TNBC, we further analyzed relevant TNBC subgroups.
Expression of the androgen receptor (AR) has been described to define a TNBC subgroup with distinct characteristics 37 . In our cohort, n=29 out of 106 TNBC cases (27.4%) expressed the AR (Fig. S1a , Table S2 ). We next analyzed the expression levels of replication stress markers in TNBC-ARand TNBC-AR + subgroups ( Fig. S1b ). Tumor expression of pRPA ( Fig. S1b , Table S2a , P=0.686) and γ-H2AX ( Fig. S1b , Table S2a , P=0.798) were not statistically different between the AR + versus AR -TNBC cases.
Likewise, tumor expression of oncogenes was similarly distributed in TNBC-ARand TNBC-AR + subgroups ( Fig. S1b , Table S2b , P>0.05 for all tests). These data indicate that in this cohort, expression of replication stress markers and expression of oncogenes are similarly distributed in TNBC-ARand TNBC-AR + subgroups.
Correlations between replication stress markers and Cdc25a, Cyclin E and c-Myc expression
To determine whether expression of Cyclin E, c-Myc or Cdc25a was associated with replication stress in our study population, we examined associations between expression of Cdc25a, Cyclin E and c-Myc with expression of replication stress markers pRPA and γ-H2AX ( Table 2) . Expression levels of pRPA were positively correlated with those of c-Myc (Table 4a , r=0.26, P<0.001), as well as expression levels of nuclear Cyclin E (Table   4a , r=0.37, P<0.001) and cytoplasmic Cyclin E (Table 4a , r=0.28, P<0.001) in the entire cohort. Among breast cancer subtypes, the strongest correlations were found in TNBC between Cyclin E and pRPA expression (Table 4a , r=0.43, P<0.001), and between c-Myc and pRPA (Table 4a , r=0.36, P<0.001). Furthermore, Cyclin E expression was strongly correlated with levels of γ-H2AX staining (Table 4b, r=0 .63, P<0.001). Spearman correlation analysis of breast cancer subtypes revealed that the association between Cyclin E and γ-H2AX expression was strongest in ER|PR -HER2 + (Table 4b, r=0 .86, P<0.001) and
TNBC (Table 4b, r=0 .71, P<0.001). Combined, these data indicate that expression of Cyclin E is associated with expression of replication stress markers in our study population, especially in the TNBC and ER|PR -HER2 + subgroups.
To test whether the association between oncogene expression and expression of replication stress markers was affected by AR expression in TNBCs, Spearman correlation analyses were performed. A stronger association between pRPA and Cyclin E was observed in ARnegative TNBCs (Table S3a, r=0.048, P=0.806). In conclusion, markers of replication stress appear equally expressed in AR-negative and AR-positive TNBCs, although the associations between replication stress (pRPA, γ-H2AX) and oncogene expression (Cdc25a, Cyclin E) are strongest in ARnegative TNBCs within our cohort.
Associations of expression of replication stress markers with clinicopathological characteristics and tumor expression of Cdc25a, Cyclin E and c-Myc
Linear regression analyses were performed to evaluate the relation between expression of replication stress markers versus clinicopathological characteristics and tumor expression of Cdc25a, Cyclin E and c-Myc. Univariate regression analysis showed that pRPA was associated with γ-H2AX (Table 5 , β=0.409, P<0.001). In contrast, oncogenes presented weak associations with pRPA ( Table 5 ). The covariates from univariate regression analyses that displayed P<0.05 were included for multivariate analyses, which showed that pRPA was weakly related to γ-H2AX (Table 5 , β=0.351, P<0.001). Conversely, tumor expression of γ-H2AX was associated with nuclear Cyclin E ( Table 6 , β=0.765, P<0.001). No significant associations were found between clinicopathological parameters and pRPA or γ-H2AX expression.
In summary, these findings indicate that replication stress measured with pRPA is related to γ-H2AX, whereas replication stress quantified with γ-H2AX is positively associated with tumor expression of nuclear Cyclin E.
Discussion
In the present study, we examined the relation between oncogene expression and replication stress marker expression in breast cancer subtypes. Our immunohistochemical analyses show that levels of replication stress and oncogene expression vary among breast cancer subtypes. Notably, the highest expression levels of replication stress markers and oncogenes were found in the TNBC and ER|PR -HER2 + subgroups. Furthermore, nuclear Cyclin E expression, and to a lesser extend c-Myc expression, were strongly associated with the levels of replication stress.
Previous immunohistochemical studies showed that Cdc25a was highly expressed in 69.6% of human breast carcinomas analyzed (n=46) 38 . A second study revealed that Cdc25a was overexpressed in 47% of breast cancer cases, in a cohort of 144 patients 16 . In comparison, in the present study 29.5% of tumors displayed strong Cdc25a staining intensity. Cdc25a has also been shown to be overexpressed in other cancer types, including high-grade serous ovarian cancer and head-and-neck squamous cell carcinoma 35, 39 , which are characterized by genomic instability 40, 41 .
Concerning c-Myc expression, our results indicated that high c-Myc expression was predominantly observed in TNBCs, and that c-Myc expression was associated with expression of the replication stress marker pRPA. These findings are in line with previous reports, showing frequent MYC amplification in TNBC 29 . Importantly, our results provide confirmation that the link between c-Myc-overexpression and induction of replication stress is also observed in patient samples 12, 31, 42 .
CCNE1 is frequently amplified in TNBC, in line with our finding that high Cyclin E expression is most prominent in TNBC cases 29 . Importantly, our observation that Cyclin E expression is associated with expression of replication stress markers is in line with experimental models, in which Cyclin E overexpression has been shown to trigger a DNA damage response 11, 15, 43 . Specific isoforms of Cyclin E, so-called low molecular-weight Cyclin E isoforms (LMW-E) are suggested to accumulate in the cytoplasm because they lack the NH 2 -terminal nuclear localization signal 44 . Although expression of cytoplasmic Cyclin E has previously been shown to induce various features that relate to replication stress, including chromosome missegregation 45 , our data show that cytoplasmic Cyclin E expression is similarly distributed among breast cancer subtypes, and is not associated with expression of replication stress markers pRPA and γ-H2AX.
Taken together, our findings indicate that among breast cancer subtypes, TNBCs and ER|PR -HER2 + tumors are characterized by overexpression of the c-Myc and Cyclin E oncogenes, and by higher expression levels of replication stress markers. These findings are relevant, as increasing numbers of drugs are being developed that target cancer cells with high levels of replication stress. Specifically, inhibitors of the cell cycle checkpoint kinases Chk1 and ATR are currently being tested in combination with genotoxic agents that interfere with DNA replication 46,47 . In parallel, inhibitors of the Wee1 kinase have been developed. The potential of Wee1 inhibition was early on attributed to high levels of replication stress 48 and preclinical data indicated that Wee1 inhibition would be preferentially effective in Cyclin E-overexpressing cancer cells 49 . In line with these data, ovarian cancer patients that responded favorably to Wee1 inhibitor treatment more frequently showed tumor overexpression of Cyclin E 50 . Based on these observations, a clinical trial testing Wee1 inhibitor treatment in patients selected on CCNE1 amplification is currently ongoing (clinicaltrials.gov identifier: NCT03253679).
Although different cell cycle checkpoint inhibitors are already in clinical development, an effective patient selection strategy is required to identify those patients who might benefit from these drugs. For breast cancer patients, our data underscore that overexpression of nuclear Cyclin E could be used as a selection criterion for treatment with drugs that target replication stress, including inhibitors of Wee1, Chk1 and ATR.
Materials and methods:
Breast cancer tissue
Immunohistochemical analysis was performed on treatment-naive tissue specimens of 558 patients with breast cancer who underwent surgery at the University Medical Center Supplemental Table 1 .
Scoring was performed semi-quantitatively by two independent researchers, without knowledge of clinical data, and was supervised by a breast cancer pathologist. Stainings were categorized according to percentages of cells that showed staining and on intensity of staining. Staining intensity was scored in three categories: 0 (negative), 1 (medium), and 2 (high). In order to calculate the score for each core, the percentage of cells in each group was multiplied by their intensity score, resulting in a range from 0 to 200 points. Next, the scores from each case and staining were averaged and considered for analysis.
For Cdc25a, only nuclear staining was considered, in line with a previous study 26 .
For Cyclin E, nuclear and cytoplasmic staining were scored individually 27 . In addition, nuclear c-Myc, pRPA and γ-H2AX stainings were evaluated. A concordance of more than 90% was found between observers. Discordant scores were reviewed and adjusted to consensus. The status of ER, PR, HER2 and AR was determined according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists by counting at least 100 cells.
Immunohistochemical stainings were considered evaluable when a tumor core contained at least 10% tumor cells. In addition, tumor stainings were included for analysis when at least 2 out of 3 cores were evaluable. Core loss over 558 cases was on average 15 
Statistical analyses
Analyses were performed on the total study population as well as on four patient subgroups based on hormone receptor status and HER2 expression. Table 1 : Clinicopathological characteristics of the study population. Overview of baseline clinical, pathological and treatment characteristics of patients from the study population cohort (n=384) and breast cancer molecular subtypes ER|PR + HER2 -(n=161), ER|PR + HER2 + (n=90), ER|PR -HER2 + (n=27) and ER|PR -HER2 -(n=106). The indicated Pvalues for tumor stage, tumor grade, radiation therapy, chemotherapy and endocrine therapy were obtained using Pearson Chi-Square tests, whereas the difference in age was assessed using a Kruskal-Wallis test.
Table 2: Relation between breast cancer subtypes and clinicopathological
characteristics in the study population. The indicated P-values were obtained using a Pearson Chi-Square test. The P-values for age were assessed using a Mann-Whitney U test. 
